WCG
RLAY icon

Weaver Consulting Group’s Relay Therapeutics RLAY Stock Holding History

Weaver Consulting Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-117
Closed -$5K – 717
2020
Q3 		$5K Buy
+117
New +$4.46K ﹤0.01% 696

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Weaver Consulting Group's RLAY Position: Q4 2020 in Review

Weaver Consulting Group sold out of Relay Therapeutics (RLAY) in Q4 2020, closing a stake of 117 shares — an estimated $5K sold.

Weaver Consulting Group first reported a position in RLAY in Q3 2020 and held it in 1 quarter. The position peaked at $5K in Q3 2020. 115 funds tracked by Wall St. Rank hold RLAY as of Q4 2020.

  • Weaver Consulting Group reported no remaining Relay Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Weaver Consulting Group sold 117 Relay Therapeutics shares in Q4 2020, an estimated $5K.
  • Weaver Consulting Group first reported a position in Relay Therapeutics in Q3 2020 and held it in 1 quarter.
  • Weaver Consulting Group's Relay Therapeutics position peaked at $5K in Q3 2020.
  • 115 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2020.

Based on Weaver Consulting Group's 13F filing for Q4 2020, filed 29 Jan 2021.